The following video is part of our "Motley Fool Conversations" series, in which David Williamson, health-care editor and analyst, and Brendan Byrnes, industrials editor and analyst, discuss topics around the investing world.
In today's edition, David and Brendan discuss some of the worst health-care stocks of 2011. These stocks fit relatively neatly into three categories: failure to launch, trial troubles, and home health-care scare. This video focuses on failure to launch -- i.e., companies whose drug candidates made it through the rigorous approval process only to be met with a lukewarm (or downright cold) commercial reception. They also discuss which of the downtrodden stocks are likely to get sales rolling in 2012.
David Williamson owns shares of Dendreon. Brendan Byrnes owns no shares of the companies mentioned here. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services recommend Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.